[go: up one dir, main page]

AR030196A1 - Compuesto que contiene cadena lateral carbociclica, composicion farmaceutica que lo contiene y uso de dicho compuesto para la fabricacion de un medicamento - Google Patents

Compuesto que contiene cadena lateral carbociclica, composicion farmaceutica que lo contiene y uso de dicho compuesto para la fabricacion de un medicamento

Info

Publication number
AR030196A1
AR030196A1 ARP010101308A ARP010101308A AR030196A1 AR 030196 A1 AR030196 A1 AR 030196A1 AR P010101308 A ARP010101308 A AR P010101308A AR P010101308 A ARP010101308 A AR P010101308A AR 030196 A1 AR030196 A1 AR 030196A1
Authority
AR
Argentina
Prior art keywords
compound
alkyl
memory
ring atoms
pharmaceutical composition
Prior art date
Application number
ARP010101308A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR030196A1 publication Critical patent/AR030196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un compuesto que contiene cadena lateral carbocíclica segun la formula (1), en donde: (A) R1 se selecciona de -OH y -NHOH; (B) R2 se selecciona de hidrogeno, alquilo, alquenilo, y otras de acuerdo con la memoria; (C) A es un alquilo monocíclilo sustituido o no sustituido que tiene de 3 a 8 átomos en el anillo; o A puede estar conectado a R2 donde, juntos, forman un alquilo monocíclico sustituido o no sustituido que tiene de 3 a 8 átomos en el anillo; (D) E y E' están enlazados en los mismos o diferentes átomos en el anillo de A e independientemente se seleccionan de un enlace covalente, alquilo de C1-4, arilo, y otros de acuerdo con la memoria; (E) (1) L y L' independientemente se seleccionan de hidrogeno, alquilo, alquenilo, alquinilo, y otros de acuerdo con memoria; o (2) L y R4 se unen para formar un anillo heterocíclico opcionalmente sustituido que contiene de 3 a 8 átomos en el anillo de los cuales de 1 a 3 son heteroátomos; o (3) L y L' se unen para formar un cicloalquilo opcionalmente sustituido que contiene de 3 a 8 átomos en el anillo de los cuales de 1 a 3 son heteroátomos; (F) G se selecciona de -S-, -O-, -N(R6)-, -C(R6)=C(R6')-, y otras de acuerdo con la memoria; y (G) Z se selecciona de: (1) cicloalquilo y heterocicloalquilo; (2) -J-(CR7R7')aR8; y otras de acuerdo con la memoria; o un isomero optico, diasteromero o enantiomero para la formula (1), o una sal farmacéuticamente aceptable, o amida, éster, o imida biohidrolizable de éste. Una composicion farmacéutica que comprende: (a) una cantidad segura y eficaz de un compuesto; (b) un portador farmacéuticamente aceptable. El uso de un compuesto que es para la fabricacion de un medicamento para tratar una enfermedad asociada con la actividad no deseada de la metaloproteasa en un sujeto mamífero. Dicho uso donde el trastorno es artritis, y se selecciona del grupo que consiste de osteoartritis y artritis reumatoide, y otras de acuerdo con la memoria.
ARP010101308A 2000-03-21 2001-03-20 Compuesto que contiene cadena lateral carbociclica, composicion farmaceutica que lo contiene y uso de dicho compuesto para la fabricacion de un medicamento AR030196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19105900P 2000-03-21 2000-03-21

Publications (1)

Publication Number Publication Date
AR030196A1 true AR030196A1 (es) 2003-08-13

Family

ID=22703974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101308A AR030196A1 (es) 2000-03-21 2001-03-20 Compuesto que contiene cadena lateral carbociclica, composicion farmaceutica que lo contiene y uso de dicho compuesto para la fabricacion de un medicamento

Country Status (21)

Country Link
US (1) US20030162778A1 (es)
EP (1) EP1265887A2 (es)
JP (1) JP2003528078A (es)
KR (1) KR20030005229A (es)
CN (1) CN1418209A (es)
AR (1) AR030196A1 (es)
AU (1) AU2001249269A1 (es)
BR (1) BR0109354A (es)
CA (1) CA2403778A1 (es)
CZ (1) CZ20023179A3 (es)
HU (1) HUP0300998A3 (es)
IL (1) IL151126A0 (es)
MA (1) MA25783A1 (es)
MX (1) MXPA02009310A (es)
NO (1) NO20024482L (es)
PE (1) PE20011187A1 (es)
PL (1) PL357275A1 (es)
RU (1) RU2002128003A (es)
SK (1) SK13362002A3 (es)
WO (1) WO2001070682A2 (es)
ZA (1) ZA200206299B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
WO1993021942A2 (en) * 1992-05-01 1993-11-11 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
AU6575394A (en) * 1993-04-27 1994-11-21 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
DE69415159T2 (de) * 1993-08-02 1999-07-22 Celltech Therapeutics Ltd., Slough, Berkshire Succinamid-derivate, verfahren zu ihrer herstellung und ihre verwendung als gelatinase- und collagenase- inhibitoren
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
NZ278627A (en) * 1994-01-20 1997-04-24 British Biotech Pharm Carboxylic and hydroxamic acid derivatives and pharmaceutical compositions
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
NZ278632A (en) * 1994-01-22 1998-04-27 British Biotech Pharm 3-aza-4-oxoheptan-1,7-dioic acid 1-amide (and 7-hydroxamic acid) derivatives
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5665753A (en) * 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
EP0763012B1 (en) * 1994-05-28 1999-06-09 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
DE69511089T2 (de) * 1994-06-22 1999-12-16 British Biotech Pharmaceuticals Ltd., Cowley Metalloproteinase-inhibitoren
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
AR002945A1 (es) * 1994-11-15 1998-05-27 Bayer Corp Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
KR100338861B1 (ko) * 1996-01-23 2003-02-20 시오노기세이야쿠가부시키가이샤 술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
JP2002514179A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼの阻害剤としてのビフェニル酪酸およびその誘導体
EP1009737A2 (en) * 1997-07-31 2000-06-21 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors

Also Published As

Publication number Publication date
SK13362002A3 (sk) 2003-04-01
RU2002128003A (ru) 2004-02-27
CN1418209A (zh) 2003-05-14
HUP0300998A2 (hu) 2003-07-28
NO20024482D0 (no) 2002-09-19
ZA200206299B (en) 2003-02-19
HUP0300998A3 (en) 2004-10-28
NO20024482L (no) 2002-09-19
KR20030005229A (ko) 2003-01-17
AU2001249269A1 (en) 2001-10-03
PE20011187A1 (es) 2001-12-12
EP1265887A2 (en) 2002-12-18
PL357275A1 (en) 2004-07-26
MXPA02009310A (es) 2003-03-12
US20030162778A1 (en) 2003-08-28
CZ20023179A3 (cs) 2003-02-12
BR0109354A (pt) 2003-04-15
IL151126A0 (en) 2003-04-10
JP2003528078A (ja) 2003-09-24
WO2001070682A2 (en) 2001-09-27
WO2001070682A3 (en) 2002-01-31
CA2403778A1 (en) 2001-09-27
MA25783A1 (fr) 2003-07-01

Similar Documents

Publication Publication Date Title
AR033356A1 (es) Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
CO4920242A1 (es) Compuestos inhibidores de metalopreoteasas 1,4-heterocicli- cos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
AR017164A1 (es) Derivados de la benzamidina, un procedimiento para prepararlos, el empleo de los mismos para preparar un medicamento, los medicamentos y laspreparaciones farmaceuticas que contienen estos derivados de la benzamidina, y un procedimiento para obtener estas preparaciones farmaceuticas.
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
AR030197A1 (es) Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
CO4920240A1 (es) Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
CO4900033A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen .
CO4900036A1 (es) Compuestos inhibidores de metaloproteasas de amina ciclica substituida composiciones farmaceuticas que los contienen y metodos para su utilizacion
CO5251429A1 (es) Derivados de ter-butil-(7-metil-imidazo(1,2-a)piridin-3- il)-amina procedimiento para su preparacion, medicamentos que los contienen, su uso para la preparacion de un medicamento para la inhibicion de la no-sintasa y composiciones farmaceuticas que l
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
CO4900045A1 (es) Compuestos inhibidores de metaloproteasas espirociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
RU94030812A (ru) Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции
ES2095976T3 (es) Compuestos de pirazolopiridina y procedimiento para su preparacion.
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion
AR035317A1 (es) Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos
PT94297A (pt) Processo para a preparacao de n-hetero-aril-purin-6-aminas e de composicoes farmaceuticas que as contem
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
AR019674A1 (es) Compuestos antitromboticos y composiciones farmaceuticas que los contienen
AR012436A1 (es) Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion.
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB
EA199800155A1 (ru) Новое соединение
AR030196A1 (es) Compuesto que contiene cadena lateral carbociclica, composicion farmaceutica que lo contiene y uso de dicho compuesto para la fabricacion de un medicamento
ES2062849T3 (es) Procedimiento para la preparacion de esteres de acido beta-cetocarboxilicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure